Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading global provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, is opening a new manufacturing facility in Carlsbad, CA dedicated to the production of Quidel’s popular QuickVue® line of products. The 128,000 square foot facility will be the company’s highest-volume production plant in the world with a mission to produce up to 600 million QuickVue rapid antigen tests per year for the detection and diagnosis of COVID-19 infections.

Quidel’s QuickVue® SARS Antigen Test and QuickVue® At-Home OTC COVID-19 Tests are visually read and provide results in 10 minutes, allowing for faster diagnosis and treatment of infectious patients. Applications for our QuickVue® COVID-19 tests range from hospitals and physician offices to schools, pharmacies, businesses, and athome use.

Throughout the pandemic, Quidel has been at the forefront of diagnostic innovation. From our Lyra® PCR tests, to our Sofia® rapid antigen tests for COVID-19, to our “ABC” combination test for the Influenza A+B and COVID-19, to our QuickVue® SARS Antigen Test and Solana® SARS-CoV-2 molecular test, we have significantly advanced the science and the scale of our operations.

The Carlsbad plant is our newest and boldest move yet. We plan to scale our operations from 50 million QuickVue tests per year to 50 million tests per month, including nonCOVID-19 diagnostic assays currently in-market or under development. To achieve this growth, we have installed numerous manufacturing lines and hired hundreds of new employees to fill job openings at all functions and levels. The new positions include purchasing, sourcing, technicians, chemists, site managers and support services.

With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to high quality, affordable testing for the good of our families, our communities, and the world.

For more information go to quidel.com